COVID-19 Retrospective Study of Chest CTs from China: What is the Re…

Adam Bernheim

Ambulatory Blood Pressure Monitoring

William White

Cardiac CT in 2023: From Anatomy to Physiology to Plaque Burden and …

Michael Gallagher

Lp(a): When to Measure it and What to Do About it

Canadian Collaborative Research Network

M. O'Donoghue

Should Colchicine Become Standard Therapy for CAD?

Canadian Collaborative Research Network

P. Ridker

Role of Coronary Calcification and Risk Stratification

The Texas Heart Institute

E. Hernandez

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

Modern Management of the LSCA in TEVAR

UPMC

M. Farber

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

How Do I Reverse Coronary Plaque?

Scripps Health

C. J. Suhar

Evaluate the Horrible Cholesterol Lp(a): Prevalence, Impact and Nove…

Scripps Health

N. Lepor

ACC 2022: Updates on Lowering LDL-C in Secondary Prevention - "Go as…

ACC 2022 Conference Coverage

R. Giugliano